SYDNEY, Australia — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide a preliminary update from the ongoing investigator-initiated Phase 2 clinical trial (NCT04906096) evaluating paxalisib as monotherapy treatment in patients with relapsed/refractory primary central nervous system lymphoma (r/r PCNSL). This is an...
treatment News
SYDNEY, Australia — Kazia Therapeutics Limited (“Kazia” or the “Company”) (NASDAQ: KZIA) today announced new data from two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) providing compelling mechanistic and early clinical evidence supporting the activity of paxalisib, the Company’s brain-penetrant dual PI3K/mTOR inhibitor, across both HER2-positive metastatic breast cancer and triple-negative...
LOS GATOS, Calif. — KDx Diagnostics, a pioneering medical device company known for its innovative noninvasive urine test for bladder cancer, the URO17Ò test, is thrilled to announce strategic partnerships with leading distributors in Europe. These partnerships mark a significant milestone for KDx as we continue our mission to make...
FORT LEE, N.J. – Kedrion Biopharma Inc., an international biopharmaceutical company specializing in the research and development, production, and commercialization of plasma-derived therapeutic products used in treating rare and serious diseases, announced today that plasminogen deficiency type 1 (PLGD-1) patients in the U.S. now have access to RYPLAZIM® (plasminogen, human-tvmh)....
FORT LEE, N.J. — Kedrion Biopharma announced today that it has received FDA approval for QIVIGY immune globulin intravenous (human)-kthm 10% liquid, indicated for treatment of adults with primary humoral immunodeficiency (PI)—a serious and often underdiagnosed group of disorders that compromise the immune system’s ability to function effectively. QIVIGY, a 10% IVIG...
FORT LEE, N.J. — Kedrion is proud to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to investigational treatment for Congenital Aceruloplasminemia, a rare genetic disorder affecting iron metabolism. This designation marks a significant milestone in Kedrion’s commitment to addressing the unmet medical needs of patients living with ultra-rare...
BOSTON, Mass. — Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for KLN-1010 for the treatment of patients with relapsed and refractory multiple myeloma. KLN-1010 is a novel in vivo gene therapy...
BALTIMORE, Maryland — Researchers at Kennedy Krieger Institute are sharing their expertise on autism spectrum disorder in a medical journal reaching thousands of pediatric professionals worldwide. The journal, Pediatric Clinics, provides the latest clinical information on health and related issues for children and adolescents. The newly released volume is titled...
LEXINGTON, Mass. — Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins, today announced the U.S. Food and...
LEXINGTON, Mass. — Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins, today announced that the U.S. Food and...